Prescription Benefits Consultant Sees Opportunities for Employers in Debate Over RebatesJuly 23rd 2019
Prescription benefits consultant Chris Robbins, chief executive of cer of Arxcel, describes the finger-pointing in Congress over lowering drug costs this way: “If it weren’t so true, it might be almost humorous.”
Medication That Inhibits PCSK9 Reduced CVD Risk in T2D PatientsJune 12th 2017
The results of the ODYSSEY-Diabetes trials focused on alirocumab, an approved monoclonal antibody that prevents PCSK-9 protein from impairing the liver’s receptors, and that antibody's effect on type 2 diabetes (T2D).
Study Finds Youth With Type 1 Diabetes Have Increased PCSK9June 9th 2017
The enzyme that affects the body's ability to process LDL cholesterol was found to be correlated with A1C levels. A symposium on the topic will be part of this weekend's 77th Scientific Sessions of the American Diabetes Association.